Welcome to our dedicated page for GE HealthCare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. (GEHC) reported that Chief People Officer Adam Y. Holton had 1,360 shares of common stock withheld on 2026-08-15 to satisfy tax withholding obligations in connection with the vesting of restricted stock units. After this tax-related share withholding, he directly holds 20,865 shares of GEHC common stock.
GE HealthCare Technologies Inc. appointed William (Bill) Grogan as Chief Financial Officer, effective September 14, 2026, succeeding the previously announced departure of Jay Saccaro. Interim CFO George Newcomb will cease serving in that interim role on that date and continue as Controller and Chief Accounting Officer.
Grogan joins from Xylem Inc., a global water solutions company with approximately $9 billion in revenue, where he has served as executive vice president and CFO since 2023 and helped integrate a $7.5 billion acquisition. His compensation package includes a $900,000 base salary, target annual bonus equal to 100% of base salary, annual LTI with a target grant date value of $3,300,000, a $550,000 cash sign-on payment, and a one-time sign-on RSU award with a grant date value of $4,000,000, plus an additional 2026 annual LTI award of $3,300,000.
The company describes itself as a leading global healthcare solutions provider with $20.6 billion in business and approximately 54,000 colleagues, focused on advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions.
Dodge & Cox filed an amended Schedule 13G reporting beneficial ownership of 47,334,058 shares of GE HealthCare Technologies Inc. common stock, representing 10.5% of the class. Dodge & Cox has sole voting power over 44,872,703 shares and sole dispositive power over all 47,334,058 shares, with no shared voting or dispositive power.
The filing states that clients of Dodge & Cox have the right to receive or direct dividends and sale proceeds for these shares. Dodge & Cox Stock Fund, a registered investment company, holds an interest in 30,726,266 shares, equal to 6.8% of the common stock class reported.
Dodge & Cox, a California-based investment manager, reports beneficial ownership of 37,864,164 shares of GE Healthcare Technologies Inc. common stock, representing 8.3% of the class. It holds sole voting power over 35,801,954 shares and sole dispositive power over all 37,864,164 shares.
The firm states that its clients have the right to receive dividends and sale proceeds on these shares. Dodge & Cox Stock Fund holds 24,247,113 shares, or 5.3% of the outstanding common stock as part of the reported position.
GE HealthCare Technologies Inc. reorganized its reporting structure by combining its Imaging and Advanced Visualization Solutions businesses into a new Advanced Imaging Solutions (AIS) segment and now reports three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS), plus an Other category for HealthCare Financial Services. Exhibit 99 provides recast unaudited historical financial information under this structure, which has no impact on previously reported financial statements.
Recast data show AIS generated $14,599 million of revenue in 2025 and $3,640 million in the quarter ended March 31, 2026; total company revenue was $20,625 million in 2025 and $5,131 million in that quarter. For the March 31, 2026 quarter, segment EBIT was $479 million for AIS, $197 million for PDx, and $10 million for PCS, with income before income taxes of $505 million.
The company also presented non‑GAAP Organic revenue measures, excluding acquisitions, dispositions, and foreign currency effects. Total Organic revenue grew 3.5% year over year in 2025 and 2.9% for the quarter ended March 31, 2026, with PDx reporting the highest Organic growth rates among the segments.
GE HealthCare Technologies Inc. reported Q2 2026 total revenues of $5,295 million, up from $5,007 million a year earlier, and first-half revenues of $10,425 million. Q2 net income attributable to GE HealthCare was $561 million (diluted EPS $1.24) versus $486 million ($1.06); first-half net income was $950 million ($2.08 diluted EPS) versus $1,049 million ($2.29).
Advanced Imaging Solutions generated Q2 revenues of $3,771 million, Pharmaceutical Diagnostics $843 million, and Patient Care Solutions $675 million. The company closed the $2,293 million cash acquisition of Intelerad, adding $1,629 million of goodwill and $845 million of definite-lived intangibles funded mainly with senior notes and a $650 million term loan.
Cash and equivalents fell to $2,108 million at June 30, 2026 from $4,515 million at the start of the year, reflecting acquisition spending and $300 million of share repurchases. Total borrowings were $10,093 million. GE HealthCare recognized $129 million of pre-tax tariff refund benefits and recorded $76 million in restructuring charges year-to-date.
GE HealthCare Technologies Inc. reported Q2 2026 revenues of $5.3 billion, up 5.7% with 3.5% organic growth. Net income attributable to GE HealthCare was $561 million, a 10.6% margin; adjusted EBIT was $750 million with a 14.2% margin. Diluted EPS was $1.24 and adjusted EPS $1.13, both benefiting from tariff refunds and a lower tax rate.
Organic orders rose 11.1%, yielding a book-to-bill of 1.15x and a $23.9 billion backlog. Advanced Imaging Solutions and Pharmaceutical Diagnostics grew strongly, while Patient Care Solutions declined and is under strategic review. Q2 free cash flow was $68 million; cash was $2.1 billion and debt $10.1 billion. The company repurchased 3.3 million shares for $200 million, declared a $0.035 dividend, and reaffirmed 2026 guidance for 3.0%–4.0% organic revenue growth, 15.4%–15.7% adjusted EBIT margin, adjusted EPS of $4.80–$5.00, and about $1.6 billion of free cash flow.
GE HealthCare Technologies Inc. reported preliminary, unaudited second quarter 2026 results. The company expects to report total revenue of $5,295 million for the three months ended June 30, 2026, up , with organic revenue of $5,182 million, reflecting 3.5% organic growth. Management also expects year-over-year growth in diluted EPS and Adjusted EPS, above its prior expectation, and reaffirmed full-year 2026 guidance.
GE HealthCare announced a leadership transition as Chief Financial Officer Jay Saccaro will resign for a role outside the medical technology industry, remaining through August 14, 2026 to support a smooth transition. George Newcomb, Controller and Chief Accounting Officer, will become interim CFO effective that date while retaining his current roles. The company emphasized that these financial results are preliminary and subject to change, with full second quarter results to be discussed on July 29, 2026.
GE HealthCare Technologies Inc. director Kevin Lobo reported an open-market purchase of 10,000 shares of common stock at $64.18 per share. After this transaction, he directly owns a total of 14,363 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. reported that Philip Rackliffe, CEO of AIS, received a grant of 16,458 restricted stock units tied to its common stock. Each unit entitles him to one share at settlement. Half of the units are scheduled to vest on May 15, 2028, and the remaining half on May 15, 2029.
Following this compensation-related award, Rackliffe directly holds 43,187 shares of GE HealthCare common stock. The grant carries no cash exercise price and represents long-term equity-based compensation rather than an open-market stock purchase.